<DOC>
	<DOC>NCT01284218</DOC>
	<brief_summary>To examine the differences in health care utilization and costs between MDD patients on adjunctive aripiprazole therapy and MDD patients on other augmentation therapies.</brief_summary>
	<brief_title>Retrospective Database Study of Real World Abilify Outcomes in Major Depressive Disorder (MDD)</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>≥1 fill for an augmentation therapy medication from Table 1 during the identification period of 01 January 2005 30 November 2008. 12 months of continuous enrollment with medical and pharmacy benefits each before the index date (preindex period) and after the index date (postindex period). ≥1 medical claim with a primary International Classification of Diseases, 9th Revision, Clinical Modification (ICD9CM) diagnosis for MDD (296.2x, 296.3x, 311.xx) during the preindex period. Age ≥18 years as of the year of the preindex period. No pharmacy claims for atypical antipsychotics, mood stabilizers, anxiolytics, anticonvulsants, or stimulants, during the preindex period. No medical claims with primary or secondary diagnoses for nonMDD episodic mood disorders or schizophrenia during the preindex or postindex periods.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>